Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway

Background: Drug resistance is well known as a major obstacle for cancer recurrence and treatment failure, leading to poor survival in pancreatic cancer, which is a highly aggressive tumor. Identifying effective strategies to overcome drug resistance would have a significant clinical impact for pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Chao, Chen, Shiyu, Guo, Yuntao, Sun, Chengyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010981/
https://www.ncbi.nlm.nih.gov/pubmed/29930725
http://dx.doi.org/10.7150/thno.23259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010981/
https://www.ncbi.nlm.nih.gov/pubmed/29930725
http://dx.doi.org/10.7150/thno.23259

Ejemplares similares